{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=18F-fludeoxyglucose+%2818F-FDG%29", "query": { "intervention": "18F-fludeoxyglucose (18F-FDG)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 94, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=18F-fludeoxyglucose+%2818F-FDG%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T04:36:50.481Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05710328", "title": "Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2-Positive Breast Carcinoma", "Invasive Breast Carcinoma" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2023-05-10", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05710328" }, { "nct_id": "NCT04665739", "title": "Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lung Neuroendocrine Tumor", "Functioning Lung Neuroendocrine Tumor", "Locally Advanced Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Tumor G1", "Lung Neuroendocrine Tumor G2", "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Neuroendocrine Tumor", "Non-Functioning Lung Neuroendocrine Tumor", "Recurrent Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-02-03", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665739" }, { "nct_id": "NCT04219904", "title": "PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Stage IA Cervical Cancer", "Stage IA1 Cervical Cancer", "Stage IA2 Cervical Cancer", "Stage IB Cervical Cancer", "Stage IB1 Cervical Cancer", "Stage IB2 Cervical Cancer", "Stage IB3 Cervical Cancer" ], "interventions": [ { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gadobutrol", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2018-09-07", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04219904" }, { "nct_id": "NCT03789240", "title": "Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Non-Hodgkin's Lymphoma", "NHL" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Bone Marrow Aspiration/Biopsy", "type": "PROCEDURE" }, { "name": "CT Scans", "type": "DIAGNOSTIC_TEST" }, { "name": "18F-FDG-PET/CT Scan15", "type": "DIAGNOSTIC_TEST" }, { "name": "Electrocardigram", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-08-22", "completion_date": "2027-01-01", "has_results": true, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03789240" }, { "nct_id": "NCT00062374", "title": "Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Stage II Gastric Cancer", "Stage III Gastric Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Fluorothymidine F-18", "type": "OTHER" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2003-06", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062374" }, { "nct_id": "NCT04933617", "title": "Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Burkitt Lymphoma", "High-grade B-cell Lymphoma", "T-cell/Histocyte-rich Large B-cell Lymphoma", "Diffuse Large B-Cell Lymphoma (DLBCL)", "Germinal Center B-cell Type (GCB)" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Copanlisib", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain", "type": "DIAGNOSTIC_TEST" }, { "name": "18F-FDG - PET", "type": "DIAGNOSTIC_TEST" }, { "name": "CT Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Lumbar Puncture (LP)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-03-24", "completion_date": "2023-11-30", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04933617" }, { "nct_id": "NCT05844306", "title": "RefleXion PET/CT Imaging Performance in Patients With Various Malignancies", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematopoietic and Lymphoid System Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DEVICE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 20, "start_date": "2023-03-15", "completion_date": "2026-08-28", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05844306" }, { "nct_id": "NCT05009979", "title": "18F-DCFPyL PET/CT in Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "F18-FDG", "type": "DRUG" }, { "name": "MRI", "type": "DEVICE" }, { "name": "CT", "type": "DEVICE" }, { "name": "F18-DCFPyL", "type": "DRUG" }, { "name": "Tumor biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2023-01-18", "completion_date": "2024-11-20", "has_results": true, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05009979" }, { "nct_id": "NCT05286801", "title": "Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Atypical Teratoid/Rhabdoid Tumor", "Epithelioid Sarcoma", "Kidney Medullary Carcinoma", "Malignant Solid Neoplasm", "Poorly Differentiated Chordoma", "Recurrent Atypical Teratoid/Rhabdoid Tumor", "Recurrent Chordoma", "Recurrent Epithelioid Sarcoma", "Recurrent Kidney Medullary Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Rhabdoid Tumor", "Refractory Atypical Teratoid/Rhabdoid Tumor", "Refractory Chordoma", "Refractory Epithelioid Sarcoma", "Refractory Kidney Medullary Carcinoma", "Refractory Malignant Solid Neoplasm", "Refractory Rhabdoid Tumor", "Rhabdoid Tumor" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tiragolumab", "type": "BIOLOGICAL" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 86, "start_date": "2022-11-17", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05286801" }, { "nct_id": "NCT07097363", "title": "Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Non-Hodgkin Lymphoma", "Burkitt Lymphoma", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Primary Mediastinal Large B-Cell Lymphoma", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2025-12-07", "completion_date": "2030-05-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-02T04:36:50.481Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07097363" } ] }